Climb Bio (NASDAQ:CLYM) Trading Down 6.1% - What's Next?

Key Points

• Climb Bio shares fell 6.1% to $15.10, with trading volume below average. The decline followed sharply elevated put-option activity, signaling increased hedging or bearish speculation.
• The company’s Phase 2 trial in China continues to advance, while HC Wainwright maintained a Buy rating and $24 price target after improving its loss estimates. Analysts overall rate the stock “Buy,” with an average target of $23.08.
• Climb Bio exceeded quarterly EPS expectations, reporting a loss of $0.18 versus the $0.21 consensus estimate. Institutional investors hold approximately 69.76% of the company’s outstanding shares.

Shares of Climb Bio, Inc. (NASDAQ:CLYM - Get Free Report) traded down 6.1% during mid-day trading on Thursday . The stock traded as low as $15.35 and last traded at $15.10. Approximately 666,332 shares traded hands during trading, a decline of 29% from the average daily volume of 943,474 shares. The stock had previously closed at $16.08.

Climb Bio News Roundup

Here are the key news stories impacting Climb Bio this week:

• Positive Sentiment: Climb Bio’s Phase 2 trial in China is advancing, providing continued progress for the company’s clinical pipeline. However, investors are also assessing whether that progress is already reflected in the valuation. Climb Bio (CLYM) Advances Phase 2 Trial In China, Is The Valuation Already Priced In?
• Positive Sentiment: HC Wainwright raised its Climb Bio loss estimates across several periods, implying better-than-previously-expected results: FY2026 EPS to $(0.76) from $(0.93), Q3 2026 to $(0.20) from $(0.23), Q4 2026 to $(0.19) from $(0.22), and FY2027 to $(0.98) from $(0.99). The firm reiterated its Buy rating and $24 price target, well above the recent trading level.
• Neutral Sentiment: Short interest was reported at zero shares as of August 25, unchanged from August 10. This indicates no measurable short-selling pressure, although the data provides little additional directional information.
• Neutral Sentiment: Unusually heavy call-option activity occurred Wednesday, with 3,024 calls traded versus typical volume of 360. The activity may reflect bullish speculation, but options volume alone does not confirm that traders expect a sustained advance.
• Negative Sentiment: Put-option activity surged Thursday to 7,091 contracts, approximately 1,046% above the average daily volume of 619. The sharp increase points to heightened hedging or bearish speculation and is the clearest near-term negative market signal.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on CLYM shares. Robert W. Baird set a $21.00 price objective on Climb Bio in a research report on Wednesday, May 6th. Royal Bank Of Canada began coverage on shares of Climb Bio in a research note on Monday, August 3rd. They issued an "outperform" rating and a $23.00 price target for the company. Wedbush reissued an "outperform" rating and issued a $20.00 target price on shares of Climb Bio in a report on Wednesday, August 19th. Guggenheim started coverage on Climb Bio in a research note on Monday, June 8th. They issued a "buy" rating and a $35.00 price target for the company. Finally, Truist Financial raised their target price on shares of Climb Bio from $17.00 to $25.00 and gave the stock a "buy" rating in a report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $23.08.

Climb Bio Trading Down 6.1%

The company has a market capitalization of $867.28 million, a PE ratio of -18.22 and a beta of 0.08. The stock's 50-day moving average is $13.69 and its two-hundred day moving average is $10.37.

Climb Bio (NASDAQ:CLYM - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.21) by $0.03. On average, equities research analysts forecast that Climb Bio, Inc. will post -0.82 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CLYM. AQR Capital Management LLC purchased a new position in shares of Climb Bio in the 1st quarter valued at about $27,000. Virtu Financial LLC acquired a new stake in shares of Climb Bio in the fourth quarter valued at approximately $43,000. Qube Research & Technologies Ltd acquired a new position in shares of Climb Bio during the 2nd quarter valued at about $43,000. Blair William & Co. IL purchased a new stake in shares of Climb Bio in the 4th quarter valued at approximately $44,000. Finally, Legal & General Group Plc purchased a new position in Climb Bio in the second quarter worth approximately $45,000. Institutional investors and hedge funds own 69.76% of the company's stock.

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company's mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio's approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source